Office of Research Integrity
Institutional Biosafety Committee (IBC)
NEW: Dual Use Research of Concern (DURC)
The MUSC Institutional Biosafety Committee (IBC) was assigned as the Institutional Review Entity for DURC at MUSC. A formal review process for potential DURC projects has been established. For more information on MUSC’s oversight of DURC, click here.
The Medical University of South Carolina (MUSC) Institutional Biosafety Committee (IBC) and the Department of University Risk Management are closely aligned in a partnership to administer the MUSC Biosafety Program, which aims to minimize risks to MUSC and surrounding community from activities involving recombinant DNA, mircoorganisms, and biological toxins.
The MUSC IBC, under its Policies and Procedures and the NIH Guidelines for Reseach Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines), oversees all research at MUSC using recombinant DNA [rDNA], microbes [of all risk groups, RG 1-4], and biotoxins. Work with all Select Agents is included, requiring IBC approval before shipping to campus. Additional guidelines are provided by the Center for Disease Control (CDC) in their Biosafety in Microbiological and Biomedical Laboratories handbook.
If you have any questions, please contact:
Dr. Yashmin Karten, IBC Administrator (firstname.lastname@example.org or 792-6521)
Dr. Chris Voelkel-Johnson, Biosafety Officer (email@example.com, 843-792-3125)
In the event of accidental exposure, the Principal Investigator and Biosafety officer (843-792-3604) should be contacted immediately by phone. In addition, immediately a First Report of Injury or Illness form ACORD form should be filled out. In case of injury, immediately proceed to employee/student health or the Emergency Room if after hours.